past
decad
ubiquitin
emerg
one
versatil
modif
role
regul
divers
array
cellular
process
control
dna
damag
repair
membran
traffick
ubiquitin
conjug
sequenti
action
three
compon
ubiquitin
activ
enzym
ubiquitin
conjug
enzym
final
ubiquitin
ligas
provid
specif
polyubiquitin
chain
form
serial
addit
ubiquitin
molecul
link
lysin
residu
preced
ubiquitin
total
seven
intern
lysin
residu
allow
divers
chain
configur
ubiquitin
play
central
role
degrad
protein
proteasom
target
direct
sort
lysosom
howev
becom
clear
revers
ubiquitin
also
crucial
mediat
within
intracellular
signal
cascad
exemplifi
nuclear
signal
protein
network
form
interact
specif
ubiquitin
bind
domain
least
class
within
human
genom
revers
ubiquitin
accomplish
deubiquitinas
dub
approxim
one
hundr
human
dub
fall
five
class
ubiquitin
specif
proteas
usp
ubiquitin
hydrolas
uch
ovarian
tumour
proteas
otu
josephin
metalloenzym
jamm
also
known
mpn
structur
function
enzym
recent
review
elsewher
review
focu
emerg
attract
target
discuss
known
function
within
pathway
german
cancer
gener
term
dub
may
influenc
stabil
key
oncogen
may
neg
regul
ubiquitin
mediat
signal
fig
oncogen
tumour
suppress
function
ascrib
individu
dub
howev
dub
may
multipl
substrat
therebi
make
difficult
determin
dub
net
oncogen
tumour
suppress
function
vivo
fig
although
knockout
overexpress
model
help
evid
suggest
function
may
vari
tissu
type
stage
malign
subset
dub
mutat
andor
alter
express
cancer
specimen
cell
line
describ
tabl
initi
catalogu
somat
mutat
cancer
cosmic
collat
gene
express
data
oncomin
provid
import
resourc
associ
dub
cancer
target
receptor
tyrosin
kinas
rtk
downstream
effector
recent
proven
one
success
avenu
drug
develop
sever
target
therapi
alreadi
clinic
practic
exampl
includ
trastuzumab
herceptin
imatinib
gleevec
contribut
significantli
treatment
overexpress
breast
cancer
gastrointestin
stromal
tumour
respect
howev
major
inhibitor
small
proport
patient
respond
treatment
respons
often
short
live
innat
acquir
resist
frequent
occur
signal
pathway
met
pathway
patient
treat
egfr
inhibitor
downstream
activ
mutat
deeper
understand
intric
regul
rtk
cascad
therefor
essenti
futur
ration
drug
develop
particular
combin
therapi
signific
endocyt
growth
factor
receptor
traffick
cancer
reflect
multitud
aberr
endocyt
machineri
describ
well
establish
ubiquitin
rtk
direct
lysosom
degrad
mutant
escap
ubiquitin
frequent
transform
follow
receptor
internalis
receptor
sort
occur
sort
endosom
receptor
incorpor
lumen
vesicl
destin
degrad
lysosom
otherwis
recycl
plasma
membran
two
endosom
dub
exert
opposit
effect
upon
fate
internalis
epiderm
growth
factor
receptor
egfr
amsh
associ
molecul
domain
stam
member
jamm
famili
metalloproteas
specif
activ
ubiquitin
linkag
knockdown
amsh
lead
increas
degrad
rate
activ
egfr
work
model
explain
observ
suggest
amsh
deubiquitin
receptor
sort
endosom
lead
recycl
plasma
membran
thu
balanc
ubiquitin
deubiquitin
activ
control
receptor
fate
interestingli
review
oncomin
databas
amsh
express
found
elev
lung
liver
bladder
colon
cancer
consist
tumour
promot
potenti
may
correl
endocyt
function
hand
also
call
ubpi
requir
downregul
egfr
met
receptor
hepatocyt
growth
factor
hgf
function
endocyt
pathway
like
pleiotrop
includ
deubiquitin
stabilis
compon
endosom
sort
machineri
hr
stam
recent
report
sirna
screen
aim
identifi
dub
regul
stabil
member
egfr
famili
undergo
activ
depend
endocytosi
identifi
homologu
also
known
yeast
compon
proteasom
lid
critic
dub
control
ubiquitin
statu
albeit
without
necessarili
affect
turnov
nevertheless
highlight
one
unanticip
effect
treatment
proteasom
inhibitor
bortezimib
may
alter
activ
receptor
could
clinic
implic
date
major
establish
role
ubiquitin
follow
rtk
stimul
promot
lysosom
degrad
receptor
recent
screen
dub
may
involv
hepatocyt
growth
factor
hgf
cell
scatter
lung
carcinoma
cell
implic
dub
process
independ
effect
met
receptor
level
suggest
hitherto
unappreci
role
event
regul
outcom
although
requir
catalyt
activ
assess
reason
suggest
set
dub
contain
could
consid
target
relev
substrat
howev
yet
identifi
recent
shown
influenc
egfr
protein
express
level
reduct
observ
follow
knockdown
convers
overexpress
catalyt
activ
result
increas
egfr
express
amongst
sever
rtk
test
met
egfr
protein
level
affect
although
exact
mechan
remain
uncertain
regul
appear
occur
level
translat
cylindromatosi
rare
famili
condit
characteris
develop
multipl
skin
tumour
known
cylindroma
mostli
scalp
earli
work
aetiolog
led
discoveri
cyld
member
usp
class
dub
inherit
autosom
domin
fashion
cylindromatosi
shown
due
mutat
cyld
gene
individu
tumour
characteris
loss
heterozygos
wherebi
second
copi
cyld
mutat
major
mutat
describ
affect
catalyt
domain
second
famili
condit
trichoepithelioma
also
caus
cyld
mutat
ident
caus
cylindromatosi
result
tumour
hair
follicl
rather
sebac
gland
occur
cylindromatosi
malign
transform
condit
rare
describ
seri
groundbreak
experi
brummelkamp
et
al
identifi
cyld
neg
regul
signal
use
shrna
librari
target
dub
identifi
candid
involv
regul
cancer
relat
pathway
demonstr
knockdown
cyld
enhanc
signal
follow
tumour
necrosi
factor
tnf
stimul
two
group
identifi
cyld
yeast
screen
protein
interact
nemo
nuclear
factor
kappa
b
essenti
modifi
key
adaptor
protein
signal
associ
cyld
pathway
suggest
applic
topic
aspirin
deriv
inhibit
activ
may
valid
therapeut
strategi
famili
cylindrimatosi
role
cyld
signal
extens
review
elsewher
describ
briefli
receptor
stimul
lead
activ
kinas
ikk
complex
compris
two
catalyt
subunit
regulatori
protein
nemo
turn
phosphoryl
phosphoryl
dissoci
undergo
polyubiquitin
degrad
proteasom
leav
activ
downstream
prolif
signal
sever
protein
involv
signal
transduct
nemo
tnf
factor
modifi
addit
link
polyubiquitin
chain
result
activ
cyld
show
preferenti
activ
polyubiquitin
chain
express
upregul
provid
neg
feedback
regul
pathway
deubiquitin
nemo
cyld
also
shown
deubiquitin
inactiv
coactiv
switch
transcript
properti
repress
activ
known
strongli
promot
cell
prolifer
oncogenesi
recent
kinas
epsilon
oncoprotein
overexpress
breast
cancer
play
critic
role
interferon
signal
pathway
shown
phosphoryl
inactiv
cyld
significantli
inactiv
cyld
necessari
transform
emerg
evid
indic
cyld
yet
independ
role
may
associ
malign
includ
regul
mitot
entri
potenti
cytokinesi
deubiquitin
trka
receptor
neuron
growth
factor
facilit
cell
migrat
whilst
latter
case
cyld
may
function
posit
regul
mitogen
motogen
process
loss
function
commonli
associ
tumourigenesi
correl
neg
role
pathway
sever
report
cyld
express
cancer
includ
lung
liver
colon
cancer
multipl
myeloma
reduc
express
also
correl
poor
prognosi
melanoma
furthermor
mice
exhibit
increas
suscept
colon
cancer
background
induc
coliti
well
skin
tumour
second
dub
also
known
tumour
necrosi
protein
neg
regul
signal
member
otu
class
dub
exert
regulatori
activ
remov
activ
ubiquitin
chain
ral
interact
protein
cyld
target
overlap
set
pathway
effector
eg
nemo
propos
cyld
may
larg
respons
constitut
inactiv
cascad
whilst
protein
level
activ
induc
respons
neg
feedback
mechan
vitro
poorli
activ
toward
free
compar
ubiquitin
chain
instead
shown
remov
chain
en
bloc
also
report
possess
activ
add
chain
although
function
may
also
involv
itch
thu
edit
ubiquitin
chain
modif
remov
one
type
ubiquitin
chain
promot
activ
replac
ubiquitin
chain
specifi
degrad
frequent
inactiv
lymphoma
restor
null
cell
line
lead
inhibit
cell
growth
induct
apoptosi
studi
establish
import
tumour
suppressor
lymphoid
malign
three
dub
implic
neg
regul
signal
otu
dub
cezann
also
known
cezann
induc
cultur
cell
lead
signal
deubiquitin
inactiv
therebi
provid
neg
feedback
loop
signal
well
associ
paralogu
shown
deubiquitin
stabilis
bind
sequest
cytoplasm
howev
case
catalyt
inact
mutant
still
abl
partial
inhibit
activ
indic
yet
unknown
mechan
action
pathway
constitut
activ
wide
varieti
cancer
intim
link
cancer
growth
metastasi
involv
five
dub
regul
underlin
import
tight
regul
normal
cell
particular
role
revers
deubiquitin
transform
growth
factor
tgf
pathway
play
dual
role
tumour
develop
earli
stage
signal
cascad
growth
inhibitori
effect
whilst
later
stage
growth
factor
promot
epitheli
mesenchym
transit
emt
outcom
signal
transduct
pathway
primarili
mediat
smad
effector
smad
well
receptor
regul
revers
ubiquitin
also
call
fam
identifi
posit
regul
signal
mean
sirna
screen
act
remov
monoubiquitin
therebi
permit
associ
subsequ
activ
gene
target
also
shown
control
protein
kinas
ampk
kinas
activ
direct
remov
ubiquitin
chain
also
call
report
interact
inhibitori
regul
ubiquitin
stabil
transcript
likewis
close
relat
jamm
dub
amsh
protein
implic
posit
regul
bone
morphogenet
protein
bmp
respons
respect
interact
inhibitori
variou
dub
shown
influenc
wnt
signal
pathway
key
mediat
cell
polar
prolifer
cellular
homeostasi
wide
implic
malign
particularli
colon
cancer
wnt
signal
increas
stabil
promot
dissoci
complex
allow
enter
nucleu
activ
tcflef
famili
transcript
factor
promot
specif
gene
express
sirna
screen
human
dub
identifi
suppressor
depend
transcript
possibl
direct
deubiquitin
transcript
factor
signalosom
associ
paralogu
also
implic
neg
regul
pathway
stabil
tumour
suppressor
adenomat
polyposi
coli
apc
therebi
promot
degrad
proteasom
contrast
otubain
dub
trabid
protein
domain
also
call
posit
regul
wnt
signal
interact
deubiquitin
apc
without
affect
stabil
line
demonstr
specif
polyubiquitin
chain
trabid
requir
transcript
cell
high
wnt
activ
includ
colorect
cancer
cell
line
may
affect
assembl
activ
transcript
complex
initi
describ
herp
simplex
encod
protein
requir
lytic
infect
term
herp
associ
usp
hausp
subsequ
link
regul
three
vital
tumour
suppressor
pten
phosphatas
tensin
homolog
foxo
forkhead
box
role
regul
complex
deubiquitin
ligas
murin
doubl
minut
homolog
ubiquitin
downregul
thu
would
posit
oppos
effect
depend
whether
predominantli
deubiquitin
rescu
current
evid
preferenti
bind
deubiquitin
therebi
lead
increas
degrad
consequ
function
scenario
consid
oncogen
howev
may
situat
balanc
revers
stabilis
act
tumour
suppressor
exampl
propos
switch
stabilis
respons
dna
damag
subsequ
activ
kinas
atm
ataxia
telangiectasia
mutat
dub
also
influenc
stabil
includ
describ
second
promin
substrat
pten
lipid
phosphatas
tumour
suppressor
act
termin
phosphatidylinositol
ptdin
signal
hydrolysi
ptdin
ptdin
possibl
second
import
tumour
suppressor
pten
mutat
wide
rang
malign
interestingli
nuclear
exclus
pten
shown
result
aggress
phenotyp
malign
although
tumour
suppress
function
nuclear
pten
remain
unclear
monoubiquitin
pten
promot
shuttl
nucleu
sequest
pml
bodi
turn
deubiquitin
pten
promot
exclus
nucleu
studi
also
show
overexpress
prostat
cancer
associ
nuclear
exclus
pten
foxo
protein
transcript
factor
tumour
suppress
function
mous
model
phosphoryl
foxo
respons
ptdin
mediat
pkbakt
activ
promot
nuclear
export
consequ
proteasom
degrad
convers
shown
result
nuclear
retent
promot
transcript
activ
describ
pten
ubiquitin
revers
ongo
work
hope
deciph
variou
contribut
differ
function
vivo
clarifi
net
result
inhibit
individu
cell
whole
organ
howev
least
face
valu
inhibit
would
appear
promis
anticanc
strategi
promot
stabilis
earli
preclin
work
inhibitor
recent
report
graner
et
al
identifi
rat
homologu
androgen
regul
dub
prostat
cancer
cell
line
express
upregul
lncap
cell
expos
dihydrotestosteron
inhibit
bicalutamid
shown
associ
stabilis
fatti
acid
synthas
protein
often
overexpress
biolog
aggress
prostat
cancer
cell
significantli
sirna
knockdown
result
apoptosi
could
revers
overexpress
fatti
acid
synthas
fa
howev
subsequ
studi
use
yeast
screen
identifi
substrat
unlik
deubiquitin
overexpress
shown
reduc
stabil
convers
suppress
led
destabilis
increas
level
activ
recent
studi
also
report
similar
role
stabilis
mdmx
anoth
neg
regul
close
structur
homologu
studi
increas
express
found
prostat
tumour
studi
overexpress
prostat
cancer
cell
line
protect
cell
apoptosi
confer
resist
chemotherapeut
agent
sirna
knockdown
led
apoptosi
interestingli
gene
profil
prostat
cancer
overexpress
show
pathway
associ
known
substrat
fatti
acid
synthas
express
also
recent
shown
correl
tumour
progress
wors
prognosi
oral
squamou
cell
carcinoma
whether
reflect
widespread
role
carcinogenesi
remain
seen
aberr
express
stabil
widespread
malign
myc
transcript
factor
bind
genom
act
core
regul
cell
growth
prolifer
apoptosi
myc
ubiquitin
rapidli
degrad
lead
toa
short
therebi
allow
exquisit
control
cellular
level
although
mutat
affect
phosphoryl
subsequ
ubiquitin
myc
describ
stabilis
myc
may
also
occur
absenc
mutat
identifi
shrna
screen
recent
shown
control
stabil
myc
antagonis
activ
ubiquitin
ligas
significantli
shrna
knockdown
led
decreas
myc
member
panel
cancer
cell
line
associ
inhibit
growth
author
also
demonstr
increas
express
signific
proport
colon
breast
carcinoma
studi
identifi
novel
mechan
cancer
cell
may
upregul
myc
may
well
prove
amen
inhibit
provid
mean
target
malign
myc
differ
studi
howev
shown
stabilis
bind
respons
dna
damag
requir
dna
damag
induc
apoptosi
inhibit
may
therefor
expect
result
significantli
differ
outcom
depend
pathway
activ
ubiquitin
hydrolas
member
uch
class
dub
one
well
studi
dub
view
associ
neurodegen
condit
includ
parkinson
diseas
wide
rang
malign
despit
vivo
function
remain
enigmat
normal
almost
exclus
express
neuron
neuroendocrin
system
gonad
aberr
express
describ
cell
lung
cancer
invas
colorect
cancer
pancreat
cancer
osteosarcoma
oesophag
cancer
overexpress
also
associ
tumour
progress
size
invas
sever
report
indic
hypomethyl
gene
lead
increas
express
gall
bladder
cancer
well
associ
progress
metastasi
colorect
cancer
hand
also
report
methyl
mediat
silenc
progress
oesophag
squamou
cell
carcinoma
gastric
cancer
pancreat
cancer
cell
line
furthermor
overexpress
associ
apoptosi
breast
cancer
cell
line
although
mutat
describ
far
associ
parkinson
diseas
rather
cancer
alter
express
appear
common
kim
et
al
recent
demonstr
role
migrat
invas
cell
lung
cancer
cell
line
sirna
knockdown
studi
addit
suggest
knockdown
result
decreas
activ
akt
downstream
effector
bheda
et
al
also
recent
describ
upregul
signal
moreov
also
show
reciproc
upregul
express
suggest
posit
feedback
loop
transform
cell
second
studi
author
use
microarray
approach
profil
gene
affect
sirna
knockdown
identifi
sever
gene
involv
apoptosi
cell
cycl
prolifer
migrat
whose
express
alter
although
data
describ
earlier
indic
import
role
malign
mechan
occur
remain
uncertain
structur
analysi
indic
promin
loop
cover
activ
site
therebi
prevent
bind
larg
protein
substrat
limit
activ
small
peptid
chain
hypothesis
may
howev
act
protein
termini
unfold
substrat
fanconi
anaemia
fa
rare
congenit
syndrom
characteris
skelet
abnorm
microcephali
progress
bone
marrow
failur
predisposit
malign
later
life
inherit
autosom
recess
diseas
clinic
phenotyp
patient
fa
vari
wide
howev
variant
share
high
frequenc
chromosom
abnorm
sensit
dna
intrastrand
crosslink
agent
thirteen
complement
group
describ
design
etc
character
mutat
gene
involv
common
pathway
regul
sens
signal
repair
dna
intrastrand
crosslink
central
fa
pathway
fanconi
anaemia
complement
group
monoubiquitin
nuclear
multiprotein
complex
incorpor
least
eight
fa
protein
event
depend
phosphoryl
serin
shown
mediat
monoubiquitin
pcna
prolifer
cell
nuclear
antigen
promot
dna
repair
chromatin
associ
enhanc
recruit
enzym
involv
transles
synthesi
respect
sirna
screen
nijman
et
al
identifi
novel
regul
inhibit
lead
accumul
monoubiquitin
whilst
pcna
substrat
deubiquitin
necessari
dna
repair
reflect
need
dynam
popul
significantli
knockout
mice
exhibit
similar
albeit
sever
phenotyp
fa
mous
model
stunt
growth
chromosom
instabl
sensit
dna
agent
sever
phenotyp
high
perinat
lethal
like
reflect
involv
substrat
includ
pcna
ubiquitin
form
found
elev
mice
stage
set
begin
think
develop
small
molecul
inhibitor
dub
facilit
develop
suitabl
high
throughput
screen
ht
platform
current
screen
use
fluoresc
substrat
sandwich
green
fluoresc
protein
gfp
terbium
undergo
fluoresc
reson
energi
transfer
one
limit
assay
suitabl
dub
process
linear
chain
eg
amsh
isopeptid
link
substrat
requir
proof
principl
achiev
identif
first
gener
inhibitor
molecul
chemic
librari
show
specif
two
unrel
small
molecul
inhibitor
target
sar
coronaviru
dub
papain
like
proteas
plpro
identifi
screen
ht
one
subsequ
optim
achiev
nanomolar
inhibit
ht
small
molecul
librari
identifi
sever
hit
select
relat
small
molecul
show
select
respect
also
report
inhibitor
develop
hybrigen
recent
shown
inhibit
rang
lead
stabilis
activ
subsequ
apoptosi
inhibit
cancer
cell
growth
select
far
demonstr
rel
small
panel
enzym
effort
need
place
upon
develop
panel
dub
enzym
characteris
select
cancer
although
defin
share
clinic
characterist
driven
remark
divers
genet
epigenet
aberr
fundament
cellular
process
futur
therapeut
strategi
depend
abil
defin
genet
makeup
individu
tumour
inhibit
specif
activ
pathway
turn
reliant
thorough
understand
regul
pathway
discuss
review
member
dub
superfamili
implic
mani
process
provid
novel
target
drug
develop
may
also
prove
use
biomark
activ
specif
pathway
earli
involv
pharmaceut
compani
combin
wealth
techniqu
built
drug
develop
analog
area
given
research
field
head
start
howev
clinic
util
target
dub
remain
proven
subject
extens
futur
research
